ID: MRFR/HC/10031-HCR | 128 Pages | Author: Rahul Gotadki | March 2024
TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT
6.1. Overview
6.2. Angiotensin-converting Enzyme (ace) Inhibitors
6.3. Diuretics
6.4. Glucophage
6.5. Others
7. GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.2. Hospital Pharmacies
7.3. Retail Pharmacies
7.4. Online Pharmacies
7.5. Others
8. GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY REGION
8.1. Overview
1.1. North America
1.1.1. US
1.1.2. Canada
1.2. Europe
1.2.1. Germany
1.2.2. France
1.2.3. UK
1.2.4. Italy
1.2.5. Spain
1.2.6. Rest of Europe
1.3. Asia-Pacific
1.3.1. China
1.3.2. India
1.3.3. Japan
1.3.4. South Korea
1.3.5. Australia
1.3.6. Rest of Asia-Pacific
1.4. Rest of the World
1.4.1. Middle East
1.4.2. Africa
1.4.3. Latin America
2. COMPETITIVE LANDSCAPE
2.1. Overview
2.2. Competitive Analysis
2.3. Market Share Analysis
2.4. Major Growth Strategy in the Global Cardiometabolic Disease Market,
2.5. Competitive Benchmarking
2.6. Leading Players in Terms of Number of Developments in the Global Cardiometabolic Disease Market,
2.7. Key developments and Growth Strategies
2.7.1. New Product Launch/Service Deployment
2.7.2. Merger & Acquisitions
2.7.3. Joint Ventures
2.8. Major Players Financial Matrix
2.8.1. Sales & Operating Income, 2022
2.8.2. Major Players R&D Expenditure. 2022
3. COMPANY PROFILES
3.1. Cardax, Inc.
3.1.1. Company Overview
3.1.2. Financial Overview
3.1.3. Products Offered
3.1.4. Key Developments
3.1.5. SWOT Analysis
3.1.6. Key Strategies
3.2. Novartis AG
3.2.1. Company Overview
3.2.2. Financial Overview
3.2.3. Products Offered
3.2.4. Key Developments
3.2.5. SWOT Analysis
3.2.6. Key Strategies
3.3. Novo Nordisk A/S
3.3.1. Company Overview
3.3.2. Financial Overview
3.3.3. Products Offered
3.3.4. Key Developments
3.3.5. SWOT Analysis
3.3.6. Key Strategies
3.4. Eli Lilly and Company
3.4.1. Company Overview
3.4.2. Financial Overview
3.4.3. Products Offered
3.4.4. Key Developments
3.4.5. SWOT Analysis
3.4.6. Key Strategies
3.5. Bayer AG
3.5.1. Company Overview
3.5.2. Financial Overview
3.5.3. Products Offered
3.5.4. Key Developments
3.5.5. SWOT Analysis
3.5.6. Key Strategies
3.6. Allergan
3.6.1. Company Overview
3.6.2. Financial Overview
3.6.3. Products Offered
3.6.4. Key Developments
3.6.5. SWOT Analysis
3.6.6. Key Strategies
3.7. Boehringer Ingelheim International GmbH
3.7.1. Company Overview
3.7.2. Financial Overview
3.7.3. Products Offered
3.7.4. Key Developments
3.7.5. SWOT Analysis
3.7.6. Key Strategies
3.8. ASTRAZENECA
3.8.1. Company Overview
3.8.2. Financial Overview
3.8.3. Products Offered
3.8.4. Key Developments
3.8.5. SWOT Analysis
3.8.6. Key Strategies
4. APPENDIX
4.1. References
4.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SYNOPSIS, 2018-2032
TABLE 2 GLOBAL CARDIOMETABOLIC DISEASE MARKET, ESTIMATES & FORECAST, 2018-2032 (USD BILLION)
TABLE 3 GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 5 NORTH AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 6 NORTH AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 7 US: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 8 US: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 9 CANADA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 10 CANADA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 1 EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 2 EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 3 GERMANY: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 4 GERMANY: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 5 FRANCE: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 6 FRANCE: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 7 ITALY: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 8 ITALY: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 9 SPAIN: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 10 SPAIN: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 11 UK: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 12 UK: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 13 REST OF EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 14 REST OF EUROPE: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 15 ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 16 ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 17 JAPAN: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 18 JAPAN: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 19 CHINA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 20 CHINA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 21 INDIA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 22 INDIA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 23 AUSTRALIA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 24 AUSTRALIA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 25 SOUTH KOREA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 26 SOUTH KOREA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 27 REST OF ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 28 REST OF ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 29 REST OF THE WORLD: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 30 REST OF THE WORLD: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 31 MIDDLE EAST: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 32 MIDDLE EAST: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 33 AFRICA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 34 AFRICA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
TABLE 35 LATIN AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY TREATMENT, 2018-2032 (USD BILLION)
TABLE 36 LATIN AMERICA: CARDIOMETABOLIC DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL CARDIOMETABOLIC DISEASE MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL CARDIOMETABOLIC DISEASE MARKET
FIGURE 4 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY TREATMENT, 2022
FIGURE 5 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2022
FIGURE 6 GLOBAL CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 7 NORTH AMERICA: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 EUROPE: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 ASIA-PACIFIC: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 REST OF THE WORLD: CARDIOMETABOLIC DISEASE MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 GLOBAL CARDIOMETABOLIC DISEASE MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 12 CARDAX, INC.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 CARDAX, INC.: SWOT ANALYSIS
FIGURE 14 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 NOVARTIS AG: SWOT ANALYSIS
FIGURE 16 NOVO NORDISK A/S: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 NOVO NORDISK A/S: SWOT ANALYSIS
FIGURE 18 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 ELI LILLY AND COMPANY: SWOT ANALYSIS
FIGURE 20 BAYER AG.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 BAYER AG.: SWOT ANALYSIS
FIGURE 22 ALLERGAN: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 ALLERGAN: SWOT ANALYSIS
FIGURE 24 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: SWOT ANALYSIS
FIGURE 26 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 ASTRAZENECA: SWOT ANALYSIS
Cardiometabolic Disease Market Segmentation
Cardiometabolic Disease Treatment Outlook (USD Billion, 2018-2032)
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Cardiometabolic Disease Distribution Channel Outlook (USD Billion, 2018-2032)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Cardiometabolic Disease Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
North America Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
North America Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
US Outlook (USD Billion, 2018-2032)
US Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
US Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
CANADA Outlook (USD Billion, 2018-2032)
CANADA Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
CANADA Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Europe Outlook (USD Billion, 2018-2032)
Europe Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Europe Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Germany Outlook (USD Billion, 2018-2032)
Germany Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Germany Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
France Outlook (USD Billion, 2018-2032)
France Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
France Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
UK Outlook (USD Billion, 2018-2032)
UK Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
UK Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
ITALY Outlook (USD Billion, 2018-2032)
ITALY Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
ITALY Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
SPAIN Outlook (USD Billion, 2018-2032)
Spain Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Spain Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Rest Of Europe Outlook (USD Billion, 2018-2032)
Rest Of Europe Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
REST OF EUROPE Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Asia-Pacific Outlook (USD Billion, 2018-2032)
Asia-Pacific Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Asia-Pacific Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
China Outlook (USD Billion, 2018-2032)
China Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
China Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Japan Outlook (USD Billion, 2018-2032)
Japan Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Japan Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
India Outlook (USD Billion, 2018-2032)
India Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
India Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Australia Outlook (USD Billion, 2018-2032)
Australia Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Australia Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Rest of Asia-Pacific Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Rest of Asia-Pacific Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Rest of the World Outlook (USD Billion, 2018-2032)
Rest of the World Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Rest of the World Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Middle East Outlook (USD Billion, 2018-2032)
Middle East Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Middle East Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Africa Outlook (USD Billion, 2018-2032)
Africa Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Africa Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Latin America Outlook (USD Billion, 2018-2032)
Latin America Cardiometabolic Disease by Treatment
Angiotensin-converting Enzyme (ace) Inhibitors
Diuretics
Glucophage
Others
Latin America Cardiometabolic Disease by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others